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ABSTRACTS A.7 
In conclusion it can be said that the necessity of systemic steroid therapy should be strongly considered in relation to the 
obtainable advantages and to the possibility of the colonization of bronchial tree by infectious agents (only 35% out of the 
patients with negative sputum culture reported frequent use of systemic steroids). Further studies will investigate the possible 
relation between systemic steroid therapy and different bacterial species. 
5. The treatment of community acquired pneumonia with fluoroquinolones 
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The combination of a /3-lactam and a macrolide is currently widely recommended treatment for community-acquired 
pneumonia (CAP) which is effective against a wide spectrum of organisms. However, because of a dramatic increase in the 
incidence of pneumococcal strains that are resistant to penicillin and other antimicrobials and because physicians cannot 
readily differentiate pneumonia caused by typical or atypical pathogens, alternative therapies are needed. 
Several new fluoroquinolones have been developed with enhanced Gram-positive and Gram-negative activities as well as a 
broader spectrum, including atypical pathogens. In this study, in vitro results and clinical efficacy and safety of the 
fluoroquinolones have been compared with that of the currently accepted therapy for CAP, based on published information. 
In vitro, moxifloxacin and trovafloxacin were the most potent fluoroquinolones with MIC90 0.125 mg/L against S. pneumoniae. 
The clinical cure rate was highest with moxifloxacin, levofloxacin and clarithromycin, reaching cures 295% of patients at the 
end of treatment and maintaining these results at follow-up. The eradication rates confirmed the potency of moxifloxacin, 
which successfully eradicated Gram-positive and Gram-negative bacilli as well as atypical pathogens. The safety profiles of 
moxifloxacin and levofloxacin were good and comparable, while grepafloxacin had a significant incidence of taste perversion 
(26%) and nausea (13.8%) and sparfloxacin exhibited photosensitivity reactions (2.4%). 
Most of the newer fluoroquinolones have an improved efficacy and safety profile compared to the earlier drugs. Overall, 
moxifloxacin appears to be a promising alternative to existing therapy with the highest in vitro potency correlating well with 
excellent clinical efficacy and good safety. 
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The duration of hospitalization of patients with pneumonia may be different in patients with or without underlying diseases. 
The aim of this study was to investigate whether hospitalization time is different between patients with pneumonia who have 
or do not have underlying comorbidity. 
We studied 70 patients with pneumonia who were hospitalized during the years 1997-1998. Thirty of the patients (18 were 
male, smokers and 12 female non-smokers), mean (SD) age 35*10 years had no underlying disease. The other 40 patients 
(32 male smokers and 8 female non-smokers ), mean (SD) age 60*5 years, had underlying disease: COPD (n= 15),coronary 
artery disease (n= lo), diabetes mellitus (n= 12) and alcoholism (n=3) . 
In the first group, the average hospitalization time was 5?2 days, whereas in the second, 9?2 days (P=O.O27).This 
difference could not be attributed to differences in treatment. The mean age of the groups was significantly different 
(P=O.O12). 
Our results suggest that the existence of underlying diseases increases the hospitalization time of patients with community- 
acquired pneumonia. 
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In an outpatient setting we used a computerised case report form also to classify exacerbations of COPD (AECB) according 
to Anthonisen criteria (AcI, AcII, AcIII) and to calculate costs of different antibiotic treatments (ATR). Between 9/98 and 
